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INTRODUCTION 
 Diabetes mellitus is a colossal health problem in India today, 
thanks to the changing  lifestyle and dietary habits. Hypertension is 
another disease with a smouldering course, which synergises with the 
deleterious effects of diabetes(1). The incidence of both these diseases has 
escalated among all age groups in recent years. 
 The association between central distribution of fat and diabetes was 
observed by Vague, in 1956. The discovery of the role of insulin 
resistance in Type – 2 DM by Reaven et al.,(2) opened up wide areas of 
study about the prevention of diabetes and its complications. The 
importance of meticulous blood pressure control in Diabetes was stressed 
by Carl –Erik Morgan and Hans Henrik Parving(3). 
 Western studies show that 30.5% of Type 2 DM  patients and 
20.40% of patients with Impaired Glucose Tolerance (IGT) are 
hypertensive.    Hyperinsulinemia   and   insulin  resistance are  the main  
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causes for this. There is compelling evidence for marked ethnic 
differences in the cardiovascular morbidity in Type 2 DM patients with 
metabolic syndrome. South Indians are more prone to complications of 
Type 2 DM compared to Caucasians with similar weight range and body 
mass index. 
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AIM OF STUDY 
1. To assess the blood pressure profile among urban female Type 2 DM 
patients. 
2. To identify the blood pressure range in relation to age, duration and 
complications of Type 2 DM. 
3. To find out the pattern of hypertension among Type 2 DM patients. 
4. To motivate for intensive therapy and blood pressure control. 
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REVIEW OF LITERATURE 
Definitions  
Diabetes   
Diabetes mellitus is a heterogeneous group of  disorders 
characterized by chronic hyperglycemia, with disturbances of 
carbohydrate, fat and protein metabolism resulting from defects in 
insulin secretion, action or both. 
Criteria for the diagnosis of diabetes mellitus(4)  
• Symptoms of diabetes plus random blood glucose concentration 
>11.1 mmol / lit   (OR)  
• Fasting plasma glucose > 7.0 mmol / lit   (OR) 
• Two hour plasma glucose > 11.1 mmol / lit during an oral glucose 
tolerance test  using 75 gm glucose load. 
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Hypertension 
Hypertension is defined as the presence of a blood pressure elevation 
(BP) to a level, that places patients at an increased risk of target organ 
damage at several vascular beds, including retina, brain, heart, kidney and 
large conduit arteries. 
Classification of blood pressure for adults >18 yrs (Joint National 
Committee VII)(5) 
Category Systolic pressure 
(mmHg) 
Diastolic 
pressure 
(mmHg) 
Normal < 120 < 80 
Pre hypertension 120 – 139 80 - 89 
Hypertension   
Stage 1 140 – 159 90 - 99 
Stage 2 >160 >100 
 
• Isolated systolic hypertension – systolic BP > 140 and diastolic BP 
< 90 mmHg. 
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Metabolic Syndrome 
 It consists of insulin resistance, glucose intolerance, a characteristic 
dyslipidemia – hypertriglyceridemia, low High Density Liproprotein 
(HDL) Cholesterol and raised Low Density Lipoprotein (LDL), with an 
excess of small dense LDL particles, truncal obesity, procoagulant 
changes  and   hyperuricemia (2,6,7). 
Adult Treatment Panel – III criteria for diagnosis of the metabolic 
syndrome(8) 
1. Central obesity  - Waist > 102 cm (men) 
> 88 cm (women) 
2. Blood pressure (mmHg)  >130/85 or treated for hypertension 
3. Dyslipidemia (mmol / lit) - Triglycerides > 1.7 
HDL – cholesterol < 1.0 (men), < 
1.3 (Women) 
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4. Dysglycemia (mmol / lit) - Fasting plasma glucose > 6.1  
Note : Three or more factors – diagnostic 
WHO criteria for diagnosis of metabolic syndrome 
Presence of diabetes and / or insulin resistance with two of the 
remaining factors 
1. Central obesity    WHR > 0.9 (men), 0.85 (women)  
     and / or BMI > 30 kg/m2 
2. Blood Pressure    > 140/90 mm Hg 
3. Dyslipidemia (mmo1/lit)   Triglyceride > 1.7, 
  HDL < 0.9 (men), <1.0 (women) 
4. Hyperglycemia (mmol/lit)  Fasting glucose > 6.1 and / or 2  
     hour post challenge glucose > 7.8 
5. Insulin resistance    Glucose uptake during   
     hyperinsulinemic euglycemic  
     clamp, in lowest quartile of  
     population 
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6. Other factors    Microalbuminuria (urine albumin  
     excretion rates > 20 μg / min or  
     albumin : creatinine ratio >  
30 mg / gm) 
Epidemiology 
 Of the estimated 155 million diabetics in the world, 100 million 
live in the Indian subcontinent and China(9). India with an estimated 40.9 
million diabetics, has earned the dubious distinction of being the Diabetic 
capital of the world. This number is estimated to rise to 69.9 million by 
the year 2025(10). 
 The Indian Council of Medical Research (ICMR) study on the 
prevalence of type 2 diabetes (1972 – 75) showed a prevalence rate of 
21% in urban, and 1.5 % in rural people below the age of 40(11) and 5% in 
urban and 2.8% in rural areas in those above 40yrs of age. The National 
Urban Diabetes Survey (NUDS), conducted in six metropolitan cities 
across India, revealed a high prevalence rate of 13.5% in Chennai(12). The 
Chennai Urban Rural Epidemiology Study (CURES) showed a 15.5% 
prevalence of diabetes using WHO criteria(13). The CURES reported a 
temporal shift in the age at diagnosis. 
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 Studies in female patients show that,  prevalence of HT is greater 
among post menopausal women. A meta analysis of data from 61 
prospective observational studies on mortality from vascular disease, 
among subjects with DM without previous vascular disease, showed that 
BP levels are strongly associated with age specific mortality rates from 
ischemic heart disease and other vascular  causes. Men and women with 
high normal BP at the baseline examination, had a higher incidence of 
cardiovascular disease on follow up than those with optimal blood 
pressure. Complications like coronary artery disease, stroke, peripheral 
arterial disease, nephropathy, retinopathy, neuropathy and 
cardiomyopathy are more common in patients with hypertension as well. 
Association between Diabetes and Hypertension 
• HT in Type -2 DM  
• HT associated with nephropathy and Type – 1 DM. 
• Coincidental Hypertension in DM 
- Essential HT 
- Isolated systolic HT 
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- Renal scarring 
• Diabetogenic anti – hypertensive drugs 
- Thiazide diuretics 
- Beta blockers 
• Drugs causing HT and glucose intolerance  
-  glucocorticoids 
- Oral contraceptive pills 
• Endocrine disorders causing  HT and glucose intolerance 
- Acromegaly 
- Cushing’s syndrome 
- Conn’s syndrome 
- Pheochromocytoma 
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Metabolic disorders associated with HT and DM 
- Central Obesity 
- Microalbuminuria 
- Low HDL cholesterol 
- High triglyceride levels 
- Insulin resistance 
- Left ventricular hypertrophy 
- Increased C-Reactive Protein 
- Endothelial dysfunction 
- Increased apolipoprotein – B levels 
- Increased fibrinogen levels 
- Increased plasminogen activator inhibitor – 1 levels 
- Increased uric acid levels 
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Peculiar characteristics of HT in type – 2 DM(14) 
1. Increased salt sensitivity 
Sensitivity to dietary salt in greatest, in those with diabetes, renal 
insufficiency, low renin status, African Americans and the elderly(15,16).  
This inturn leads to volume expansion in those with unrestricted salt 
intake. 
 
2. Loss of nocturnal dip in BP 
Normotensives and most hypertensives have a circadian pattern of 
blood pressure and heart rate during 24 hour ambulatory monitoring(17). 
BP is highest in awake state and lowest, (falls by 10-15%) during sleep, a 
pattern called ‘dipping’. Diabetics have a <10% decline in BP at night(18) 
and this attributes to an increased risk of stroke and myocardial 
infarction. Therefore, drugs providing consistent and sustained 24 hour 
BP control will be advantageous(19). 
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3. Microalbuminuria 
In type 2 DM, microalbuminuria is associated with insulin 
resistance, salt sensitivity, loss of nocturnal dipping and left ventricular 
hypertrophy. Increased systolic BP is an important determining factor in 
the progression of microalbuminuria(20). 
4. Isolated systolic hypertension 
As atherosclerosis progresses in type 2 DM, larger arteries lose 
elasticity and become rigid. The arterial system is incapable of expansion 
for any given volume of blood ejected from the left ventricle and the 
systolic BP rises disproportionately. Isolated systolic hypertension thus 
occurs, at a younger age in diabetics.  
5. Orthostatic hypotension 
In normal individuals pooling of blood in the periphery, causes fall 
in stroke volume and systolic BP and rise in systemic vascular resistance, 
diastolic BP and heart rate on standing. This phenomenon is exaggerated 
in diabetics, leading to orthostatic hypotension, which in turn causes 
cerebral hypoperfusion. 
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In hyperadrenergic diabetics, orthostatic hypertension occurs. β 
blockers are undesirable in such patients. Clonidine might blunt such a 
response(21). 
PATHOGENESIS OF HYPERTENSION IN TYPE -2 DM 
 The state of hyperinsulinemia that exists in type 2 DM is associated 
with generation of reactive oxygen species(22) that scavenge Nitric Oxide 
(NO) and impair its bioactivity. This leads to defective endothelium 
dependent vasodilatation and plays a key role in progression of 
atherosclerosis(23). Moreover, inability to counteract platelet derived 
growth factor activity and promotion of phenylation of RAS proteins 
precipitate atherosclerosis(24). 
 Insulin also acts on the distal renal tubule to retain Na+ ions and 
water (23,25). It also stimulates the cell membrane Na+ - K+ adenosine 
triphosphatase, which raises intracellular Na+ in vascular smooth muscle, 
by increasing cytosolic Ca2+ levels. This directly enhances contractility 
and peripheral vascular resistance(26,27). Insulin stimulates proliferation of 
vascular smooth muscle cells, which results in medial hypertrophy and 
ultimately leads to hypertension(28).  
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The main determinants of hypertension in a patient with Type 2 
DM are total body fluid volume, sodium content, insulin levels and 
glucose levels. 
Sodium and total body fluid volume 
 Total body exchangeable sodium in diabetic patients is 10% higher 
than non diabetics. The increase in exchangeable sodium is explained 
partially by active reabsorption  of glucose and ketones in the kidney, as 
sodium salts. Increased extracellular osmolarity caused by hyperglycemia 
leads to water retention in the vascular space. 
 Diabetes is associated with decreased Plasma Renin Activity 
(PRA), compared to normal individuals. Impaired β - adrenergic 
regulation of renin secretion and decreased prostacyclin secretion 
contribute to low PRA in Diabetes Mellitus. Moreover, inactive renin is 
increased in DM and is associated with an increased incidence of 
microvascular disease. Hyporeninemic hypoaldosteronism seen in 
diabetic nephropathy is associated with elevated arterial pressure and 
hyperkalemia. Despite the Low PRA activity, the Renin – Angiotensin – 
Aldosterone system seems to contribute to the pathogenesis of 
hypertension. Increased activity of tissue Renin Angiotensin System, 
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especially vascular renin with local generation of Angiotensin II and 
enhanced arterial sensitivity to renin, has been proposed as possible 
mechanisms. 
 Though Atrial Natriuretic Peptide (ANP) levels are relatively high 
among diabetics, its action can be blunted. This could promote sodium  
retention and hypertension. This is another theory postulated. The 
increased ANP levels can promote glomerular hyperfiltration in diabetics 
and lead to hypertrophy in course of time. 
 Erythrocyte Sodium – Lithium counter transport system activity is 
increased in Type 2 DM. This leads to increased Sodium reabsorption in 
proximal convoluted tubules of the kidney. 
Insulin and Diabetic hypertension 
 Hypertension is associated with hyperinsulinemia in obese 
diabetics, non diabetic obese individuals and essential hypertension. 
Reduced tissue response to insulin is the key factor leading to 
hyperinsulinemia. There is a negative correlation between insulin 
sensitivity and systolic blood pressure. Presence of hypertension in 
diabetics further aggravates insulin resistance. 
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 Type 2 DM patients have reduced glucose uptake through the 
oxidative pathway and reduced effects of insulin on suppression of 
hepatic glucose output. Truncal adiposity without marked increase in 
BMI, is linked with HT and  hyperinsulinemia.   Intraabdominal 
adipocytes readily release Free Fatty Acids in response to adrenergic 
stimulation, due to increased sensitivity of omental adipocytes to β3 
adrenergic stimulation. Increased Fatty  Acids inturn impair hepatic 
insulin clearance, and muscle glucose uptake, and is associated with 
increased vascular reactivity. Increased Free  Fatty Acids also  increase 
sensitivity to α1 adrenoreceptor mediated vasoconstriction. Activation of 
protein kinase – C, increased generation of cyclooxygenase metabolites 
and inhibition of Nitric Oxide production lead to this process of 
vasoconstriction. 
 Normally, insulin stimulates muscle blood flow by its vasodilatory 
effect and this facilitates glucose delivery and uptake. In Type 2 DM, due 
to specific impairment of sympathetic neural responsiveness in skeletal 
muscle, insulin fails to enhance muscle blood flow. This could lead to 
diminished peripheral blood flow and glucose delivery and contribute to 
hypertension. 
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 Increased serum leptin levels in diabetics is directly related to 
Blood Pressure and heart rate. Insulin increases Vascular Smooth Muscle 
Cell cytosolic calcium, through activation of voltage dependent calcium 
channels. The mitogenic effect of insulin on vascular smooth muscle 
cells, further enhances their proliferation. Proinsulin, the precursor of 
insulin stimulates endothelin secretion and also increases  tissue 
Plasminogen Activator Inhibitor (PAI) in endothelial cells. These 
mechanisms lead to early development of hypertension and also enhance 
coagulation. 
 Insulin increases LDL binding to smooth muscle cells, fibroblasts 
and monocytes. Monocytes, are the precursors of foam cells. In these 
cells, insulin stimulates the activity of 3-hydroxy – 3 methyl glutaryl 
coenzyme A (HMG – CoA) reductase, the rate limiting enzyme of 
cholesterol synthesis, and thus enhances atherosclerosis. 
 Magnesium  may also mediate a nexus between HT, DM and 
insulin resistance. Total red blood cell magnesium levels usually increase 
in response to increased insulin levels. This effect is impaired in Type  2 
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DM. The resultant magnesium depletion downregulates the activity of 
rate limiting glycolytic enzymes and reduces insulin sensitivity. Reduced 
magnesium levels also increase vascular reactivity. 
Role of Glucose in Diabetic hypertension 
 Increased glucose level causes upregulation of Platelet Derived 
Growth Factor (PDGF) receptor expression and thus exerts a mitogenic 
effect on vascular smooth muscle cell. It also directly enhances 
endothelin secretion. Glucose also exerts a direct toxic effect on 
endothelial cells, resulting in accelerated cell death. Angiotensin 
Converting Enzyme (ACE) activity is increased by glucose. Glucose 
mediates decrease in hydrogen peroxide scavenging and thus result in 
increased oxidative tress in vascular tissue. This leads to early oxidative 
modification of proteins in the endothelium, with loss of functions of key 
enzymes like glucose–6–phosphate dehydrogenase and glyceraldehyde-3- 
phosphate dehydrogenase. This loss of functional endothelial cells, 
coupled with reduced NO levels causes arterial vasoconstriction. Finally, 
glucose enhances LDL oxidation, which leads to  increased microvascular 
complications. 
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 Circulating glucose binds non enzymatically to proteins, leading to 
formation  of highly reactive Advanced Glycosylation End Products. 
These in turn bind selectively with basement membrane proteins and 
promote vasculopathy. Advanced glycosylation end products also 
promote the progression of  medial hypertrophy and inhibit the 
vasodialatory effect of NO. 
Impact of Hypertension in Diabetes  
Many hypertensive diabetic patients show signs of target organ 
damage mainly affecting the cardiovascular system(29). Deaths from 
coronary heart disease increase by 2-5 times in diabetics with 
hypertension. Impaired left ventricular relaxation and increased left 
ventricular mass(30) are independent predictors of death from coronary 
heart disease. 
 Hypertension also predisposes to nephropathy and retinopathy. 
Diabetics should therefore be screened on diagnosis and atleast annually 
there after, for hypertension. 
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TARGET BLOOD PRESSURE IN TYPE 2 DM 
 The Hypertension Optimal Treatment (HOT) trial and UKPDS 
demonstrated that, patients assigned to lower BP levels, had improved 
outcome, particularly, in stroke prevention (31).  A target BP of <130/80 is 
recommended by the Seventh Joint National Committee (JNC) on 
prevention, detection, evaluation and treatment of high BP and by the 
American Diabetic Association. In patients with microalbuminuria and 
renal insufficiency blood pressure goal is < 125/75 mm Hg. 
INVESTIGATION OF HYPERTENSION IN TYPE 2 DM  
i. Rule out rare causes of secondary hypertension 
ii. Cardiac function assessment 
- 12 lead Electrocardiogram 
- Echocardiography 
- Exercise testing / Stress echo cardiogram 
- 24 hour holter monitoring 
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iii. Renal function assessment 
- Microalbuminuria 
- look for cellular casts in urine  
- Blood urea nitrogen and serum creatinine estimation 
- Glomerular Filtration Rate   Measurement 
- Isotope renogram to look for renal artery stenosis (or) 
Renal doppler studies 
 iv. Lipid profile 
MANAGEMENT OF HYPERTENSION IN TYPE 2 DM 
Non pharmacological therapy 
- Exercise – aerobic physical activity 
- Smoking cessation 
- Adequate Potassium and Magnesium intake 
- Alcohol intake <1 ounce / day 
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- Diet rich in fruits and vegetables and low in fat 
- Reduced sodium intake < 100 mmol / day. 
Pharmalogical treatment 
Diuretics 
 Furosemide, bendroflumethiazide, spironolactone and indapamide 
are suitable for use in diabetics.  Lower dosages should be used, in 
combination with potassium supplements or potassium sparing drugs. 
Thiazides may aggravate dyslipidemia and hyperglycemia and should be 
used with caution(32). 
Beta blockers 
 Beta blockers lower BP, heart rate and cardiac output. But, they 
may aggravate hyperglycemia and dyslipidemia through inhibition of β-2 
adrenergic mediated insulin release and decreased insulin action in 
peripheral tissues. They may also interfere with the counterregulatory 
effects of catecholamines, causing hypoglycemia unawareness.  
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Recent studies show that metoprolol and carvedilol(33,34) can be 
used favourably in cardiac failure patients(35). In the UKPDS, atenolol 
was comparable to captopril(36).  
Calcium channel antagonists 
 Nondihydropyridine calcium channel antagonists reduce 
proteinuria in diabetic nephropathy. They are also indicated in patients 
with angina or supraventricular tachycardia. They are better at preventing 
stroke than beta blockers and thiazide diuretics(37).  
Angiotensin – Converting Enzyme (ACE) inhibitors  
 ACE inhibitors may improve insulin sensitivity (38). Hypoglycemia 
is rarely reported(39). 
 They reduce albuminuria and delay progression of renal damage in 
nephropathy(40). They improve left ventricular function. Ramipril reduces 
cardiovascular morbidity in diabetics, with or without preexisting heart 
disease(41). However, they may precipitate Acute Renal Failure in elderly 
and cause potassium retention. So creatinine and K+ levels should be 
monitored periodically. 
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Angiotensin Receptor Blockers (ARB) 
  They slow the progression of nephropathy in diabetes patients with 
albumunuria(42). Losartan is better than atenolol in reducing total 
mortality in type 2 DM patients with HT and left ventricular 
hypertrophy(43). 
Alpha -1 Adrenoreceptor antagonists 
 They can improve dyslipidemia and insulin senstitivity and lower 
BP effectively. 
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TREATMENT ALGORITHM FOR HT IN TYPE 2 DM 
Treatment goal – BP < 130/80 
 
 
  
 
 
 
 
 
 
A - ACE  inhibitor / Angiotensin Receptor Blocker 
B - Beta Blocker 
C - Calcium channel blocker 
Non - Pharmacologic therapy
Goal not achieved
 - Continue non - pharmacologic therapy
- Initiate pharmacologic therapy with 
   a thiazide diuretic
Goal not achieved
Add second drug in alphabetic order 
(A, B, C)
Goal not achieved
Increase drug dose Add another drug
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Identification of the antihypertensive agent of choice for Type 
2DM may appear rather questionable since multiple drugs are required in 
most patients to achieve the target of <  130/80, as observed by Kaplan. 
In the HOT study, the large majority of patients randomized to a diastolic  
BP < 80 mm Hg were on double or  triple drug therapy.  Likewise, in the 
UKPDS, 29% of the patients randomized to tighter BP control, were on 
three drugs and 34% were on two drugs. Studies on diabetic nephropathy, 
revealed that most patients were on 2 to 3 drugs in addition to an 
Angiotensin Receptor Blocker. 
OUTCOME OF TREATING HYPERTENSION IN DM 
 Effective treatment of hypertension slows down the progression of 
diabetic nephropathy, by lowering albumin excretion and the rate of fall 
of glomerular function. As per the UKPDS study, tighter BP control 
causes significant reduction in the risk of stroke (44%) heart failure 
(56%), myocardial infarction and peripheral vascular disease. 
Interestingly the most powerful effects were related to reduction in the 
two major microvascular complications – nephropathy and  retinopathy. 
Thus effective treatment seems to be cost effective as per the health 
conomics analysis in UKPDS45. 
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The Bergamo Nephrologic Diabetes Complications Trial,  
concluded that in subjects with Type 2 DM with hypertension, 
normoalbuminuria and normal renal function, ACE inhibitor therapy with 
trandolapril and verapamil (or)  trandolapril alone,  prevented the onset of 
microalbuminuria. The Reduction of Endpoints in NIDDM with the 
Angiotension II Antagonist Losartan (RENAAL) study showed that 
Losartan therapy was associated with a 28% reduction in the risk of End 
Stage Renal Disease and a 25% reduction in doubling of serum creatinine 
level in patients with early diabetic nephropathy. 
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MATERIALS AND METHODS 
Setting 
 The study  was conducted, among outpatients attending the 
Diabetology department in Govt. Royapettah Hospital. 
Study Population 
 The study was conducted over an eight month period from 
December 2006 to July 2007. 80 female patients were selected randomly. 
Cases of Impaired Glucose Tolerance and Impaired Fasting Glucose were 
excluded. Patients with Type 2 DM for atleast  one year were chosen. 
Informed consent was obtained from all patients. 
 Those with BP > 140/90 on the first visit were reviewed twice and 
those with persistently high values were diagnosed as hypertensive.  
Patients with history of hypertension who were already on treatment,  
were also included among hypertensives. Of the 85 patients, chosen, three 
were found to be hypothyroid, one had congenital heart disease and 
another had chronic kidney disease and were excluded.  
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Inclusion criteria 
Patients with Type 2DM for atleast 1 year who were on regular 
treatment with oral hypoglycemic agents or insulin or both.  
Exclusion criteria 
- Patients of age < 30 
- Patients with congenital heart disease 
- Pregnant women 
- Cases of hypothyroidism 
- Smokers 
Basic data including name, sex, occupation, income, present and 
past history was obtained. Anthropometric measurements including 
height in metres, weight in kilograms, waist and hip circumference in 
centimeters was noted. Waist circumference was recorded, as the smallest 
circumference between the lower costal margin and iliac crest. Hip 
circumference was recorded at the widest part of the gluteal region. Vital 
signs were recorded. BP recordings were repeated on 3 different 
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occasions in patients with BP > 140/90 on the first visit. Only those with 
persistently elevated values and those with a history of Hypertension 
were included among hypertensive. General and detailed systemic 
examination was done in all patients. Renal parameters, urine 
examination, electro cardiogram and chest X-ray was done in all patients. 
Reference values used 
- Hypertension - BP > 140/90 mm Hg (or) H/o hypertension on 
treatment 
- Total cholesterol < 200 mg/dl - Normal  
- BMI 
Values > 25 kg / m2 i.e. overweight and obese taken as 
abnormal. 
- WHR > 0.85 was taken as indicator of abdominal obesity. 
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OBSERVATIONS AND ANALYSIS 
 Among the 80 patients included in the study 57.5% (46 subjects) 
were hypertensive. Another 15% (12 subjects), were noted to have BP 
above the ADA target range of < 130/80. Among the hypertensives 
approximately 45.6% were newly diagnosed. 
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Correlation between age of the patient and prevalence of HT 
Age Group 
No.of 
patients 
No with 
HT 
% with  hypertension 
30 – 39 6 1 16.7% 
40 – 49 27 13 48.2% 
50 – 59 23 14 60.9% 
60 - 69 16 12 75% 
70 – 79 8 6 75% 
 
The prevalence of HT in the 30 to 39 age group was 16.7%. There 
was a gradual increase in prevalence of HT with increase in age. The 70-
79 age group showed a prevalence of 75% 
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Correlation between duration of diabetes and prevalence of HT 
Duration of 
diabetes 
No of 
patients 
No with 
HT 
% with  hypertension 
0 – 4 33 17 51.5% 
5 – 8 31 17 54.8% 
9 – 12 11 7 63.6% 
13 – 16 4 4 100% 
17 – 20 1 1 100% 
 
 Among the  33 patients diagnosed to have diabetes within 4 years, 
51.5% were hypertensive. The prevalence was found to be as high as 
100% in those with diabetes for longer duration. 
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Correlation between HT and  Coronary Artery 
Disease (CAD) in Type  2 DM 
Age Group HT CAD CAD+HT % of CAD with HT 
30 – 39 1 0 0 - 
40 – 49 13 2 1 50% 
50 – 59 14 4 2 50% 
60 – 69 12 3 2 66.6% 
70 – 79 6 2 2 100% 
  12 9 75% 
 
 Totally 12 patients had  CAD including those with ECG changes 
and those with symptoms of CAD.  Among them 75% (9) were 
hypertensive. 
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Correlation  of hypercholesterolemia with HT 
 
Age Group HT 
 
Cholesterol HT + Cholesterol 
% of  
Cholesterol 
with HT  
30 – 39 1 1 0 - 
40 – 49 13 5 2 40% 
50 – 59 14 5 3 60% 
60 – 69 12 2 1 50% 
70 – 79 6 2 2 100% 
  15 8 53.3% 
 
 Among the 80 patients, 18.7% had hypercholesterolemia. Of the 15 
patients with hypercholesterolemia 58.3% (8 patients) were hypertensive. 
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Correlation of Cerebrovascular Accidents (CVA) and 
Peripheral vascular disease (PVD) with HT 
Age Group HT PVD PVD+HT 
% CVA CVA + 
HT 
% of  CVA 
with HT 
30 – 39 1 0 0 0 - - - 
40 – 49 13 1 0 0 - - - 
50 – 59 14 2 1 50% 1 - - 
60 – 69 12 1 1 100% - - - 
70 – 79 6 1 1 100% 1 1 100% 
  5 3 60% 2 1 50% 
 
 Only 5 patients had peripheral vascular disease. Of them 60% were 
hypertensive.  Only 2 patients in the study had history of CVA. Among 
them one patient was hypertensive. 
 In the Edinberg Artery study, systolic BP was related 
independently to claudication with an odds ratio of 1.2. Systolic BP was 
documented as a risk factor in the Framingham study as well. 
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Correlation of  Diabetic Nephropathy, Retinopathy  
and Neuropathy with HT  
Age 
Group HT 
Nephro 
pathy 
Nephro 
+ HT 
% DR HT+ 
DR 
% Neuro 
pathy 
Neuro 
+ HT %  
30 – 39 1 - - - - - -   - 
40 – 49 13 1 1 100% 1 1 100% 1 - 0 
50 – 59 14 2 2 100% 1 1 100% 1 1 100% 
60 – 69 12 1 1 100% 2 1 50% 2 1 50% 
70 – 79 6 1 1 100% 1 1 100% 2 1 50% 
  5 5 100% 5 4 80% 6 3 50% 
  
 All the  5 patients who had diabetic nephropathy were hypertensive 
and so were 80% of those with diabetic retinopathy. Of the 6 patients 
with diabetic neuropathy, only 3 were hypertensive. The association with 
hypertension was maximum in patients with nephropathy. The prevalence 
of neuropathy was more common in normotensives than hypertensives. 
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Correlation of  BMI and WHR  with hypertension in  
type 2 DM patients 
Age Group HT BMI > 25 
BMI + 
HT 
% W/H 
Ratio 
W/H + 
HT %  
30 – 39 1 3 - - 5 1 20% 
40 – 49 13 13 10 76.9% 16 10 62.5% 
50 – 59 14 15 10 66.7% 17 11 64.7% 
60 – 69 12 9 5 55.5% 11 10 90.9% 
70 – 79 6 2 1 50% 6 3 50% 
 46 42 26 61.9% 55 35 63.6% 
 
 More than 50% of the patients were overweight of whom 61.9% 
had hypertension. 50 patients were found to have WHR  > 0.85. Among 
them 63.6% were hypertensive. Only 42 patients were overweight, but 55 
patients were found to have increased Waist Hip Ratio. 
 50 
 
Pattern of HT among newly detected patients 
Stage No.of patients 
ISH 4 
I 4 
II 5 
 
ISH – Isolated systolic HT 
 20 patients were newly diagnosed to have HT during the study. 
Majority of them had stage I hypertension. 4 of them, all aged 60 and 
above, had Isolated Systolic Hypertension. 
Correlation between menopausal status and hypertension 
71.2% of the patients were post menopausal. Among them 65.4% 
were hypertensive. Only 43.5% of premenopausal females had 
hypertension. 
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Prevalence of HT among female Type  2DM patients with 
complications 
CAD 75% 
Nephropathy 100% 
Retinopathy 80% 
CVA 50% 
PVD 60% 
Neuropathy 50% 
 
Among female patients with complications Type 2  DM, Nephropathy 
had maximum association with Hypertension. 80% of patients with 
Retinopathy and 75% of those with CAD had Hypertension. The association 
was less among patients with CVA and Neuropathy. 
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DISCUSSION  
 In this study 57.5% of urban female patients with Type 2DM, were 
found to be hypertensive. According to WHO studies, 30.50% of those 
with type 2 DM have HT. The increase in prevalence in this study can be 
attributed to genetic and ethnic differences. Genetic susceptibility, 
increased prevalence of central obesity and elevated pro inflammatory 
markers like C-Reactive Protein (CRP) may be important causes. 
Moreover, levels of physical activity and fitness among South Asian 
females are lower, compared to Europeans.46 Ward et al, postulated that 
increased glucocorticoid action in Indians with increased BMI, may be 
the cause for increased prevalence of HT.47 
 In this study, there was a gradual and steady increase in prevalence 
of HT from 16.7% in the 30-39 age group to 75% in the 70-79 age group. 
This is similar to the observations made by Baris et al, of the 
Hypertension and Diabetes Executive Committee Working Group, in 
which there was an increased likelihood of DM with increasing age.48 
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 Vasan et al who investigated 6859 patients of the Framingham 
Heart Study, found that the prevalence of HT increased with duration of 
DM. He also observed that, even patients with a high normal base line 
BP, had an increase in incidence of CAD, on follow up.49 Likewise, in 
this study the prevalence of HT increased from 51.5% in recently 
detected to 100% in those with a longer duration of DM. More over, 15 
patients had BP values in the high normal range and as per the 
Framingham Heart study, have an increased risk of CAD. 
 The prevalence of CAD was observed to be 8.8% in normotensives 
and 19.5% in hypertensives. This was in accordance with observations by 
Grundy et al. He observed that risk of CAD was almost twice in patients 
with co-existent HT. 
 The total cholesterol values were elevated in only 18.75% of the 
diabetics in our study. Many earlier studies, revealed a normal or high 
normal level of total cholesterol, with increased Triglyceride and 
decreased HDL - cholesterol in diabetics. Due to limitation in 
investigation, TGL and HDL-C levels could not be assessed. 
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 The prevalence of CVA was decreased marginally, in 
hypertensives (2.16%) when compared to nonmotensives (2.94%).  This 
might be attributed to the smaller number of patients included in the 
study. There was a minimal increase in prevalence of peripheral arterial 
disease, 6.52% in hypertensive as compared to 5.55% in those who were 
normotensive. This was in contrast, with other studies, that show a 50% 
increased prevalence. Similarly, in contrast to other studies, no 
association was noted between HT and diabetic neuropathy, in this study. 
 All the patients with DM nephropathy were found to be 
hypertensive Retinopathy was four times more common in hypertensives 
compared to others.. This was in accordance with the observations made 
in UKPDS, where in there was a predisposition to the development of 
retinopathy and nephropathy in hypertensives.  
 More than 50% of patients in the study group were overweight  
(BMI ≥ 25). 56.5% of hypertensives were obese, as opposed to, 47% 
prevalence in normotensives. WHR  ≥ 0.85 was seen in 68.8% of the 
study group. Among them, 63.6% were hypertensive. Similar 
observations were made by Bakris et al and Sower JR in their studies. 
 57 
 
 Only few studies have been conducted regarding the prevalence of 
DM and its complications in females. In 1984, Hartz et al., in a survey  of 
30,000 women reported a higher incidence of DM in women with a 
greater proportion of body fat in the waist. Studies by Mohan et al., show 
a higher body fat in Indian females compared to males. 
                                                       
Sex BMI (median) Fat % (Median) 
Male 22.0 22.7% 
Female 22.7 37.4% 
 
The modified ATP III criteria for Indians suggests a waist 
circumferences of  > 85 cm and BP > 130/85 for the diagnosis of 
metabolic syndrome in females. 
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CONCLUSION 
 
 The prevalence of HT in urban, female, South Indian population, 
with Type 2DM, was 57.5%.  
¾ There was an increase in prevalence of HT with increasing age. 
¾ Duration of DM was positively associated with prevalence of HT. 
¾ The prevalence of obesity, particularly central obesity was greater 
among hypertensives. 
¾ The prevalence of  CAD in hypertensives was twice that of 
normotensives. 
¾ Retinopathy and Nephropathy showed maximum association with 
HT. 
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¾ A considerable percentage of hypertensives (37.5%) were newly 
detected. Periodic screening of DM patients for HT is therefore 
mandatory.  
¾ Patient with high normal BP levels who are also at increased risk 
of CAD must be identified and treated as per guidelines. 
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SUMMARY 
 80 urban female patients with Type 2 DM, with atleast one year 
duration of DM, were chosen. BP was recorded as per guidelines, and 
hypertensive patients were identified. BMI and WHR were calculated and 
patients were evaluated for complications of DM. The prevalence of 
complications of DM in patients with HT was compared with those with 
normal BP. 
 The prevalence of HT in urban females with Type 2DM was 
57.5%. There was an increased prevalence of CAD and even greater 
prevalence of Nephropathy and Retinopathy in hypertensive patients. The 
prevalence of hypertension is more in older patients. 37.5% of 
hypertensives were newly detected and referred for registration in 
hypertension outpatient department. 
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PROFORMA  
Basic Data 
Name :      Income : 
Age :      Diet  : 
Occupation : 
Anthropometry  
Height :   Weight :  BMI : 
Waist circumference :  
Hip circumference :     WHR: 
History : 
 H/o DM  
   Duration 
  Treatment Details 
 H/o HT  
  H/o CAD 
  H/o dyslipidemia 
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H/o smoking and alcohol  
H/o Thyroid dysfunction 
H/o TIA/CVA 
H/o drug intake 
Family History 
Obesity   Hypercholesterolemia 
DM   CAD 
SHT   Malignancies  
Menstrual history 
General Examination  
 Anemia   
 Acanthosis Nigricans 
 Pedal edema   
Goitre  
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 Facial puffiness 
Foot ulcers  
Discolouration of feet 
Vital Signs  
 PR  -   Peripheral pulses     -  
  BP  -   Postural fall in BP -  
  JVP  -  Resp. rate  - 
Systemic Examination  
CVS   S1S2 -    Murmurs    - 
   S3/S4 -  Pericardialfriction rub  -  
RS   
Breath sounds    
Pleural rub 
Added sounds  
Abdomen   
CNS  
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Fundii 
Investigations 
Urine - albumin 
    sugar 
deposits 
 Blood urea  
Serum creatinine 
 Blood sugar 
 Serum Cholesterol 
Electrocardiogram  
Chest X-ray 
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1. 31 23 8 145 52 24.7 80 90 0.89 140/80         
2. 32 30 2 140 60 30 102 95 1.07 120/80   +      
3. 35 33 2 150 51 22.7 75 85 0.88 120/80         
4. 36 35 1 150 54 24 76 90 0.84 110/80         
5. 39 32 7 151 65 28.5 93 95 0.97 130/80         
6. 39 35 4 150 72 29.6 98 99 0.99 130/82         
7. 40 39 1 145 70 33 92 90 1.02 140/92 + + +      
8. 40 35 5 150 54 24 80 88 0.9 110/80         
9. 40 39 1 168 76 26.9 73 87 0.83 140/100 +        
10. 40 30 10 162 50 19 68 80 0.85 150/102 +   + +    
11. 41 39 2 145 60 28.5 15 85 0.88 150/102 +        
12. 42 37 5 156 45 18.5 65 82 0.79 110/80   +      
13. 42 33 9 162 65 24.8 68 88 0.77 120.80         
14. 44 39 5 153 51 21.8 76 88 0.86 120/74        + 
15. 44 42 1 152 57 24.6 72 83 0.86 130/86         
16. 44 35 9 150 40 17.8 63 79 0.79 136/74      +   
17. 44 39 5 156 50 20.5 71 82 0.87 110/76         
18. 45 40 5 153 56 23.9 75 88 0.85 140/92         
19. 45 42 3 157 64 26.0 78 85 0.92 170/110 +  +      
20. 45 43 2 160 63 24.6 72 82 0.87 130/80         
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21. 45 42 3 161 63 24.3 74 88 0.84 130/84         
22. 45 44 1 144 56 27.0 82 85 0.96 170/112 +        
23. 45 40 5 165 51 18.8 65 80 0.81 140/86         
24. 45 37 8 148 70 31.9 78 84 0.92 150/96 +        
25. 46 41 5 160 44 17.2 62 78 0.82 150/80         
26. 47 43 4 150 62 27.5 70 85 0.82 130/84         
27. 47 39 8 138 40 21.1 62 76 0.82 110/80   +      
28. 47 41 6 139 54 28 78 86 0.91 110/80 +        
29. 48 40 8 143 61 29.9 82 92 0.89 110/70  +       
30. 48 39 9 150 38 16.9 60 80 0.75 110/70   +      
31. 49 40 9 162 78 29.8 76 87 0.87 130/92 +        
32. 49 42 9 147 49 22.7 69 84 0.82 160/96 +        
33. 49 45 4 162 78 29.8 88 87 1.01 130/96         
34. 50 49 1 151 62 27.2 75 82 0.91 140/92         
35. 50 44 6 154 46 19.4 67 84 0.79 120/80 +        
36. 50 49 1 136 55 29.9 82 85 0.96 160/100         
37. 50 42 8 156 60 24.7 72 88 0.81 180/110 + +     +  
38. 50 46 4 154 70 29.5 78 85 0.91 120/80 +        
39. 50 49 1 153 62 26.5 72 82 0.88 130/82   +      
40. 51 49 2 159 70 27.7 80 88 0.91 136/80 +        
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41. 52 47 5 154 70 29.5 82 85 0.96 150/110 +  +      
42. 53 51 2 154 55 23.3 66 84 0.78 150/96         
43. 53 43 10 152 56 24.2 70 84 0.83 130/84         
44. 55 45 10 154 65 27.4 84 89 0.94 150/98   +    +  
45. 55 52 3 138 41 21.6 63 80 0.79 120/80         
46. 55 48 7 153 65 27.8 76 85 0.89 110/80         
47. 55 45 10 152 60 25.9 84 89 0.94 120/80   +     + 
48. 55 52 3 152 60 25.9 76 88 0.86 160/96         
49. 55 48 7 160 62 24.3 78 84 0.9 134/84         
50. 56 50 6 145 64 30.5 95 94 1.01 160/100 +        
51. 56 53 3 138 55 28.9 90 90 1.0 128/70  +       
52. 57 42 15 145 45 21.4 69 82 0.84 160/98    + +    
53. 58 54 4 152 60 25.9 76 85 0.89 110/80         
54. 58 45 13 162 57 21.8 78 88 0.87 150/94      +   
55. 58 52 6 146 72 33.8 94 92 1.02 164/100 + + +      
56. 59 54 5 146 70 32.9 92 95 0.96 110/80  +       
57. 60 55 5 150 67 29.8 89 95 0.94 160/104 +  +      
58. 60 50 10 149 56 25.2 72 85 0.84 110/80      +   
59. 60 49 11 155 58 24.2 74 80 0.86 120/80 +        
60. 60 55 5 154 70 29.5 85 90 0.94 120/80         
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61. 60 57 3 150 60 24.7 73 86 0.85 132/80  + +      
62. 60 54 6 144 58 28.0 78 86 0.90 170/88         
63. 60 55 5 154 65 31.4 84 86 0.98 120/80         
64. 60 58 2 149 55 24.8 73 80 0.91 140/94         
65. 61 46 15 152 68 29.4 78 90 0.87 140/80         
66. 62 57 5 149 55 24.8 74 84 0.88 130/90 + +       
67. 63 60 3 164 74 27.5 75 91 0.82 130/94 +        
68. 65 51 14 152 75 32.5 90 88 0.75 150/94    + + +   
69. 65 62 3 152 57 24.7 87 90 0.97 146/90 +        
70. 65 60 5 154 58 24.5 70 80 0.81 140/100 + +  +     
71. 65 63 2 144 52 25.1 68 83 0.82 140/80         
72. 65 60 5 168 76 26.6 78 84 0.92 140/96         
73. 70 69 1 151 53 23.2 66 84 0.79 140/100 +  +      
74. 71 63 8 154 64 27.0 80 92 0.87 130/80      +   
75. 74 71 3 164 60 22.3 69 84 0.82 160/98  +     +  
76. 75 70 5 152 52 22.5 76 89 0.85 110/80         
77. 76 58 18 152 79 34.2 93 93 1.0 170/120 + + +  +    
78. 76 66 10 148 50 22.8 72 83 0.86 160/98      +   
79. 79 73 6 156 54 22.2 76 84 0.90 144/80         
80. 79 74 5 152 65 28.1 72 84 0.85 144/90         
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ABBREVIATIONS 
- ACE - Angiotensin Converting Enzyme. 
- ADA - American Diabetic Association  
- ATP- Adult Treatment Panel 
- BMI - Body Mass Index 
- BP - Blood Pressure 
- CAD - Coronary Artery Disease  
- CRP - C- Reactive Protein  
- CURES - Chennai Urban Rural Epidemiological Study 
- CVA - Cerebrovascular Accident  
- DM - Diabetes Mellitus  
- DR. Diabetic Retinopathy  
- HDL.C- High Density Lipoprotein - Cholesterol 
- HOT - Hypertension Optimal Treatment  
- HT - Hypertension 
- ICMR - Indian Council of Medical Research  
- IFG - Impaired Fasting Glucose     
- IGT - Impaired Glucose Tolerance  
- ISH - Isolated Systolic Hypertension 
 82 
 
- LDL - Low Density Lipoprotein  
- NUDS - National Urban Diabetic Survey  
- PDGF - Platelet Derived Growth Factor. 
- PVD - Peripheral Vascular Disease 
- TGL - Triglyceride 
- UKPDS - United Kingdom Prospective Diabetes Study  
- WHR - Waist/Hip Ratio  
- WHO - World Health Organisation  
 
